Home Cart Sign in  
Chemical Structure| 5373-11-5 Chemical Structure| 5373-11-5

Structure of Cynaroside
CAS No.: 5373-11-5

Chemical Structure| 5373-11-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cynaroside is a flavone, a flavonoid-like chemical compound.

Synonyms: Luteolin 7-glucoside; Luteolin 7-O-β-D-glucoside; Luteolin 7-O-Glucoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cynaroside

CAS No. :5373-11-5
Formula : C21H20O11
M.W : 448.38
SMILES Code : O=C(C=C(C1=CC(O)=C(O)C=C1)OC2=CC(O[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)=C4)C2=C4O
Synonyms :
Luteolin 7-glucoside; Luteolin 7-O-β-D-glucoside; Luteolin 7-O-Glucoside
MDL No. :MFCD06799436
InChI Key :PEFNSGRTCBGNAN-QNDFHXLGSA-N
Pubchem ID :5280637

Safety of Cynaroside

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Cynaroside

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCT116 cells 12.5, 25, 50 µM 24, 48, 72 h Inhibited CRC cell proliferation Molecules. 2024 Mar 28;29(7):1508
RKO cells 12.5, 25, 50 µM 24, 48, 72 h Inhibited CRC cell proliferation Molecules. 2024 Mar 28;29(7):1508
LoVo cells 12.5, 25, 50 µM 24, 48, 72 h Inhibited CRC cell proliferation Molecules. 2024 Mar 28;29(7):1508
THP-1-differentiated macrophages 20 μM 48 h To evaluate the antileishmanial activity of Cynaroside against intra-macrophagic amastigotes. Results showed that Cynaroside reduced parasite load by 50% at 20 μM concentration and by 80% when combined with 4 μM miltefosine. Biosci Rep. 2021 Jan 29;41(1):BSR20203857
HEKn (human normal keratinocytes) 20 μM 48 h to 6 days LUT-7G leads to modification of the cell cycle with accumulation of cells in G1 phase and induces keratinocyte differentiation, increasing KRT10 expression. Cell Death Dis. 2016 Aug 18;7(8):e2344

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Methotrexate-induced enteritis model Gavage 10, 20, or 40 mg/kg 7 days Cynaroside alleviates methotrexate-induced enteritis by inhibiting NLRP3 inflammasome activation Front Immunol. 2024 May 21;15:1405084
C57BL/6J mice Unilateral ureteral obstruction (UUO) model Intraperitoneal injection 10 mg/kg Once daily for 8 consecutive days Cynaroside significantly ameliorated tubular injury and interstitial fibrosis while improving renal function. Mechanistically, Cyn inhibited the expression of fibrosis-related proteins and suppressed Smad2/3 phosphorylation. Additionally, Cyn reduced myofibroblast accumulation by inhibiting epithelial–mesenchymal transition, as indicated by increased E-cadherin expression and decreased levels of mesenchymal markers. Cyn also reduced oxidative stress by downregulating the prooxidant enzyme NADPH oxidase 4 and restoring antioxidant enzymes. Furthermore, Cyn attenuated ferroptosis by regulating key proteins, including acyl-CoA synthetase long-chain family member 4, transferrin receptor 1, and glutathione peroxidase 4, while also restoring glutathione levels. Cyn alleviated endoplasmic reticulum stress, as evidenced by the downregulation of key markers such as glucose-regulated protein 78 and activating transcription factor 6, and reduced inflammation, as confirmed by decreased macrophage infiltration and lower cytokine production. Redox Rep. 2025 Dec;30(1):2500271
Nude BALB/C mice HCT116 subcutaneous xenograft model Intraperitoneal injection 25, 50 mg/kg Every 3 days for 18 days Inhibited tumor growth and reduced tumor weight Molecules. 2024 Mar 28;29(7):1508
Mice CCl4-induced liver fibrosis model Not explicitly mentioned 10-20 mg/kg 35 days Evaluate the therapeutic effect of CYN on liver fibrosis, results showed CYN treatment attenuated the progression of liver fibrosis Pharmaceuticals (Basel). 2023 Apr 6;16(4):548

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.23mL

0.45mL

0.22mL

11.15mL

2.23mL

1.12mL

22.30mL

4.46mL

2.23mL

References

 

Historical Records

Categories